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Abstract 
The therapeutic benefit of self-monitoring blood pressure in stroke patients is uncertain. We 
investigated the effect of self-monitoring, with or without guided antihypertensive 
management, compared to usual care in patients with a recent cerebrovascular event. No 
between-group differences in blood pressure at outcome were found, but blood pressure self-
monitoring and management was well tolerated. 
 
Introduction 
Hypertension is the most important modifiable risk factor for primary and secondary stroke 
prevention, even modest reductions in clinic blood pressure (BP) of approximately 
10/5mmHg being associated with a 30% risk reduction [1]. Despite the existence of effective 
treatments, rates of BP control post-stroke are poor, a recent cohort reporting only 16% of 
patients achieving clinic BP ≤130/80mmHg six months after their event [2]. Studies suggest 
that self-BP monitoring (SBPM) may improve BP control, its use resulting in lower BP levels 
and increased achievement of targets compared to usual management, particularly if 
combined with complementary strategies, such as telemonitoring of results, or guided 
antihypertensive self-management [3]. However, studies to date have not addressed the use of 
SBPM in high-risk groups. Here we report the results of the TEST-BP trial, which aimed to 
determine whether SBPM with or without guided self-management of BP treatment resulted 
in lower BP levels and better control than usual care in hypertensive patients with a recent 
stroke or transient ischaemic attack (TIA). 
 
Methods 
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TEST-BP was a randomised, blinded end-point, parallel group controlled trial 
(ClinicalTrials.gov reference no. NCT02947490). Summary methods are described, with full 
methodology available (online supplement). Eligible patients were adults with a recent 
mild/moderate stroke or TIA, all requiring BP treatment for secondary prevention. Patients 
with life expectancy below six months or cognitive impairment were excluded. Ethical 
approval for the trial was granted (Research Ethics Committee East of England – Norfolk 
(ref: 11/EE/0147)). All participants provided written informed consent. At enrolment, 
participants were randomised via a concealed web-based system to Treatment As Usual 
(TAU), Self-MONitoring only (S-MON), or Self-monitoring with guided self-MANagement 
of BP (S-MAN).   
 
Ambulatory BP monitoring ((ABPM) Spacelabs 90207 monitor, Spacelabs Healthcare Ltd. 
(UK), Hertford, UK), undertaken as per guidelines [4], was performed at baseline and six 
months in the three groups. BP management for TAU participants was by their General 
Practitioner (GP) only. The intervention groups performed self-monitoring, as per guidelines 
[4], at six weeks, three and five months post-randomisation. S-MON patients used a validated 
monitor (Omron 705IT, Omron Healthcare UK Ltd., Milton Keynes, UK) with readings 
passed to the GP for management. S-MAN patients used a validated monitor (A&D UA-
767PBT, A&D Instruments Ltd., Abingdon, UK) with telemonitoring (iModem; Netmedical, 
Utrecht, Netherlands), readings going directly to the trial team. Changes to antihypertensive 
treatment in S-MAN group were made jointly by the patient and the supervising stroke trial 
clinician, but informing the patient’s GP. British guidelines current at trial inception 
recommended a secondary stroke prevention target clinic BP of ≤130/80mmHg, with out-of-
office BP targets adjusted down by 10/5mmHg due to expected differences in measurement 
methods [5], so out-of-office target BP was ≤120/75mmHg. 
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The primary outcome was difference in daytime ambulatory systolic BP (SBP) at six months. 
Secondary outcomes were (i) differences in mean daytime ambulatory diastolic BP (DBP) at 
six months, (ii) differences in antihypertensive medication changes, (iii) adverse events.  
 
Participants with <14 daytime ABPM readings or non-compliant with self-monitoring were 
excluded from analysis. To detect a difference in mean daytime ambulatory SBP of 6mmHg, 
with a power of 0.8 at the 5% significance level, assuming a standard deviation of 10.3mmHg 
for daytime ABPM [6], required 48 participants per group.  
 
Outcomes Analysis 
Data were analysed using SPSS version 23.0 on an intention to treat (ITT) basis. Continuous 
data are presented as mean (standard deviation) or mean (95% confidence interval (CI)), 
discrete data as median (interquartile range (IQR)). Independent samples t-tests assessed 
between-group differences in mean BP at outcome and Chi-squared tests assessed 
proportions of participants who were normotensive at outcome and proportions of 
participants who had medication changes. Mann-Whitney U tests assessed between-group 
differences in medication changes. Each intervention group was compared separately to 
control, with exploratory comparison of the intervention groups only where both were 
significantly different to control, to reduce the risk of a false positive outcome and to 
eliminate potential bias from using distinct control groups [7]. Sensitivity analysis accounting 
for missing ABPM data was conducted after imputation by predictive mean matching.  
 
Results 
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Recruitment ran from 20
th
 December 2012 to 14
th
 March 2016, ending when target numbers 
were achieved. Progress through the trial is shown in Figure 1, with baseline demographics 
in Table I. 
 
There were no significant between-group differences in the primary outcome of mean 
daytime ambulatory SBP at six months (difference TAU minus S-MON 2.69mmHg [95% CI 
-2.59 to 7.97, p=0.31], TAU minus S-MAN 3.00mmHg [95% CI -2.53 to 8.54, p=0.28]) or in 
mean daytime ambulatory DBP (Table II). SBPM did not result in more participants 
achieving target BP (daytime ABPM ≤120/75mmHg) (TAU 12/52 [23%], S-MON 8/51 
[16%], S-MAN 13/51 [26%], p>0.05). Subgroup analysis of those with uncontrolled baseline 
BP (daytime ABPM >120/75mmHg) gave similar results (data in online supplement), as did 
the sensitivity analysis. 
 
A greater proportion of S-MAN participants had their antihypertensive therapy adjusted 
compared to control (TAU 31% vs. S-MAN 63% p=0.001), though there was no difference 
with S-MON (31% vs. 43% p=0.19). The difference with S-MAN was driven by a greater 
number of dose increases (TAU vs. S-MAN p=<0.0001). The number of dose decreases, 
additional, or discontinued medications did not differ.  
 
Ninety-two percent of SBPM recording sets were completed. Only one participant was non-
compliant with self-monitoring. In comparison, most TAU participants consulted their GP 
once during the trial (median 1.0, IQR 0.0-2.0). Rates of reported side effects were similar in 
all groups and no major adverse events were recorded.  
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Discussion 
Our findings, in agreement with comparable studies, showed that SBPM alone, or combined 
with telemonitoring and guided therapy management, did not result in lower BP levels or 
improved BP control at six months compared to usual care, despite good adherence. In a trial 
of SBPM alone vs. usual care in hypertensive stroke patients, clinic BP at six or 12 months 
was not significantly different with intervention [8]. Post-hoc analysis suggested a benefit in 
participants with baseline clinic BP >140/90mmHg, but we did not find this. Similarly, when 
investigating SBPM with guided self-management vs. usual care in a mixed high-risk 
population, intervention did not result in lower clinic BP at 12 months in the subgroup with 
stroke/TIA [9]. Conversely, a feasibility study of SBPM telemonitoring vs. usual care post-
stroke reported ambulatory SBP reductions of 10.1mmHg at six months with intervention 
compared to 3.8mmHg with control [6]. The only meta-analysis to assess patients with 
cerebrovascular disease as a subgroup found no benefit with intervention, though this finding 
may reflect small numbers and few trials employing SBPM with additional strategies [3].  
 
SBPM cannot intrinsically lower BP; rather its effect is mediated through therapeutic 
intensification [8-10], as we found, which is less likely to occur in patients with controlled 
BP. Alternatively, patients with physical (or cognitive) disability post-stroke may gain less 
benefit from SBPM due to therapeutic inertia, as noted by Kerry et al. [8]. These findings 
suggest that not all patients post-stroke will benefit from SBPM.   
 
Strengths of this study include the use of the gold-standard ABPM for the BP outcome 
measure [4], differentiating it from most similar studies and reducing measurement and 
observer bias, and the simultaneous comparison of two interventions of differing intensity. 
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The main limitation is the smaller between-group BP difference than planned in our sample 
size calculation, hence our study may be underpowered to make firm conclusions about the 
significance of a more modest, but potentially clinically important SBPM effect. Secondly, 
our self-monitoring target may have been too low (just 10 participants reached target BP on 
the final self-monitoring), with recent comparisons suggesting that out-of-office values are on 
average 4/3 mmHg lower than clinic measurements [11]. Thirdly, although most participants 
had baseline daytime ABPM above our defined target, mean BP levels were approximately 
135/75mmHg and all participants were on treatment, potentially limiting the benefit of the 
interventions. Finally, the use of different home monitors may have introduced measurement 
bias, though we would stress that both are validated. 
 
In summary, SBPM with or without guided self-management of antihypertensive therapy was 
safe and well tolerated, but did not improve overall BP control in these post-stroke 
participants. The small reductions in BP demonstrated with SBPM in this trial may still be 
clinically significant and warrant further investigation to identify potential subgroups where 
such therapy may be clinically beneficial.  
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Table I: Comparison of baseline characteristics between the three trial groups in TEST-BP. 
Values presented are mean (SD) or frequency (%). 
   Treatment 
as usual 
N=52 
Self-
monitoring 
only 
N=51 
Self-monitoring 
and self-
management 
N=51 
Age (years)  72.3 (9.8) 74.5 (9.6) 73.8 (10.7) 
Sex Male 34 (65%) 33 (65%) 34 (67%) 
Ethnicity  White 51 (98%) 50 (98%) 51 (100%) 
 Black 1 (2%) 0 (0%) 0 (0%) 
 Asian 0 (0%) 1 (2%) 0 (0%) 
Diagnosis  TIA 34 (65%) 33 (65%) 34 (67%) 
 Stroke 18 (35%) 18 (35%) 17 (33%) 
Baseline clinic blood 
pressure (mmHg) 
SBP 152.4 (18.1) 154.5 (18.3) 148.3 (21.3) 
 DBP 82.4 (12.0) 87.2 (9.8) 81.7 (13.1) 
Baseline clinic blood 
pressure ≤130/80mmHg 
 2 (4%) 2 (4%) 6 (16%) 
Baseline daytime 
ambulatory blood 
pressure (mmHg) 
SBP 134.4 (14.3) 135.3 (14.7) 133.7 (13.0) 
 DBP 75.4 (9.5) 76.6 (8.0) 75.9 (8.5) 
Baseline daytime 
ambulatory blood 
 6 (12%) 8 (16%) 7 (14%) 
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pressure ≤120/75mmHg 
First self-monitored 
blood pressure (mmHg) 
SBP - 142.5 (14.5) 138.4 (16.6) 
 DBP - 77.8 (7.6) 78.8 (9.7) 
Past Medical History Hypertension 36 (69%) 33 (65%) 40 (78%) 
 Transient 
ischaemic attack 
38 (73%) 31 (61%) 37 (73%) 
 Stroke 19 (37%) 20 (39%) 21 (41%) 
 Ischaemic heart 
disease 
8 (15%) 11 (22%) 13 (26%) 
 Diabetes 15 (29%) 10 (20%) 12 (24%) 
 Chronic kidney 
disease 
2 (4%) 2 (4%) 2 (4%) 
Montreal cognitive 
assessment score  
 26.0 (3.0) 25.7 (2.9) 24.9 (3.7) 
Number of baseline 
antihypertensives 
 1.6 (0.8) 1.4 (0.8) 1.9 (1.0) 
Antihypertensive 
medications 
ACE inhibitor or 
angiotensin 
receptor blocker 
36 (69%) 37 (73%) 43 (84%) 
 Beta blocker 17 (33%) 9 (18%) 12 (24%) 
 Calcium channel 
blocker 
23 (44%) 16 (31%) 24 (47%) 
 Diuretic 8 (15%) 5 (10%) 12 (24%) 
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 Alpha blocker 2 (4%) 4 (8%) 2 (4%) 
 Other - - 4 (8%) 
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Table II: Ambulatory systolic and diastolic blood pressure at six months for each trial arm 
and the between-group differences. Values presented are mean (SD) for within-group blood 
pressure levels and mean (95% confidence interval) for between-group differences. 
 
 
 
TAU 
S-
MON 
S-
MAN 
Difference 
TAU vs S-
MON 
P 
value 
Difference 
TAU vs S-
MAN 
P 
value 
Daytime 
ambulatory 
systolic blood 
pressure 
(mmHg) 
130.8 
(15.5) 
128.2 
(11.2) 
127.8 
(12.7) 
2.69  
(-2.59 to 
7.97) 
0.31 
3.00  
(-2.53 to  
8.54) 
0.28 
Daytime 
ambulatory 
diastolic blood 
pressure 
(mmHg) 
72.3 
(10.2) 
73.5 
(7.6) 
74.3 
(10.5) 
-1.18 
 (-4.70 to  
2.34) 
0.51 
-2.03  
(-6.08 to  
2.03) 
0.32 
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Figure Legends 
Figure 1: CONSORT flow diagram. 
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